Side Effects of tipranavir: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of tipranavir
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of tipranavir: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of tipranavir: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Tipranavir is a new nonpeptidic protease inhibitor that exhibits potent and specific activity against both HIV-1 and -2. When combined with ritonavir, it effectively reduces viral load and suppresses both wild-type and protease inhibitor-resistant virus. 7

Tipranavir, when administered alone, is a CYP3A inducer, while ritonavir is a CYP3A inhibitor. The drug interactions between tipranavir coadministered with ritonavir and other antiretroviral medications or with other medications commonly used in HIV therapy are well characterized. 8

Early trials demonstrated that tipranavir/ritonavir was safe and well tolerated, with mild gastrointestinal side effects. 7

Tipranavir has been linked to intracranial hemorrhage. 1

In a study of 10 patients receiving tipranavir/ritonavir 500/200 bid, 3 out of 5 patients who switched doses experienced benefits in terms of reducing aminotransferases and total cholesterol. Fasting triglycerides were also reduced in 2 of them. Plasma HIV-RNA remained undetectable in all patients. 5

Reasons for Side Effects

Tipranavir's side effects are likely due to its mechanism of action and metabolic pathways. Tipranavir is metabolized by the cytochrome P4503A4 enzyme and its pharmacokinetic parameters are enhanced when combined with ritonavir. 7

Tipranavir is known to interact with other medications, including fluconazole, atorvastatin, clarithromycin, and rifabutin. 7

Tipranavir may inhibit the enzyme ZMPSTE24, leading to an accumulation of prelamin A, which could play a role in the side effects of this drug. 3

Common Side Effects

Gastrointestinal Side Effects

Tipranavir has been associated with mild gastrointestinal side effects, such as diarrhea, nausea, vomiting, and abdominal pain. 7

Liver Enzyme Elevation

Tipranavir has been observed to cause elevated liver enzymes in some patients. 5

Intracranial Hemorrhage

Tipranavir has been associated with intracranial hemorrhage. 1

Managing Side Effects

Gastrointestinal Side Effects

Managing gastrointestinal side effects may involve dietary adjustments, medication, or other interventions. 7

Liver Enzyme Elevation

Regular monitoring and management are recommended to address elevated liver enzymes. 5

Intracranial Hemorrhage

Regular monitoring and management are essential to minimize the risk of intracranial hemorrhage. 1

Comparison Across Studies

Commonalities Across Studies

Across multiple studies, tipranavir has shown to be effective against HIV and has been generally well-tolerated. However, it's important to note that tipranavir can cause side effects, including gastrointestinal issues, elevated liver enzymes, and potentially intracranial hemorrhage. 2 7 10 9 8 1 3 12 4 5 6

Differences Across Studies

Research has reported varying incidences and severities of tipranavir's side effects. Differences have also been observed regarding drug interactions between tipranavir and other medications. 2 7 10 9 8 1 3 12 4 5 6

Considerations for Real-Life Application

Tipranavir should be used with caution and under the guidance of a healthcare professional. Tipranavir can interact with other medications and may cause side effects. If you are receiving tipranavir, consult with your doctor and follow their instructions. 2 7 10 9 8 1 3 12 4 5 6

Limitations of Current Research

More research is needed to fully understand the long-term effects of tipranavir. 2 7 10 9 8 1 3 12 4 5 6

Future Research Directions

Further research is needed to examine the long-term effects of tipranavir, its interactions with other medications, and the mechanisms behind its side effects. 2 7 10 9 8 1 3 12 4 5 6

Conclusion

Tipranavir is an effective treatment for HIV infection, but it can cause side effects. It's crucial to use it under the guidance of a healthcare professional and to be aware of potential interactions with other medications. Continued research is needed to better understand the long-term effects and side effects of tipranavir. 2 7 10 9 8 1 3 12 4 5 6

Literature analysis of 12 papers
Positive Content
9
Neutral Content
0
Negative Content
3
Article Type
2
0
0
8
12
3.

HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.

Author: CoffinierCatherine, HudonSarah E, FarberEmily A, ChangSandy Y, HrycynaChristine A, YoungStephen G, FongLoren G

Lipodystrophy
Side effects

HIV protease inhibitors (HIV-PIs) can cause an accumulation of prelamin A, which could play a role in the side effects of these drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.

Author: MastrolorenzoAntonio, RusconiStefano, ScozzafavaAndrea, BarbaroGiuseppe, SupuranClaudiu T

HIV infection treatment
Side effects

Highly active antiretroviral therapy (HAART) has significantly changed the course of HIV infection. The use of protease inhibitors (PIs) is a key component of HAART, with nine drugs currently available. PIs are effective in treating HIV infection and have also shown potential in other therapeutic areas, such as antitumor, antibacterial, antifungal, and antimalarial therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.

Author: MorelloJudit, Rodríguez-NovoaSonia, BlancoFrancisco, VispoEugenia, BarreiroPablo, Gonzalez-PardoGema, Jiménez-NácherInmaculada, González-LahozJuan, SorianoVincent

HIV suppression
Reduced aminotransferases
Reduced cholesterol
Reduced triglycerides
Pill burden
Side effects

Tipranavir is a potent protease inhibitor but has a high pill burden and frequent side effects. This study found that reducing the ritonavir dose in patients taking tipranavir/ritonavir resulted in decreased liver enzymes and cholesterol levels in some patients without affecting viral suppression.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Tipranavir: a novel second-generation nonpeptidic protease inhibitor.

Author: KandulaVijayabhaskar Reddy, KhanlouHomayoun, FarthingCharles

HIV-1 and -2 treatment
Drug-drug interactions
Gastrointestinal side effects

This paper discusses tipranavir, a new nonpeptidic protease inhibitor for the treatment of HIV-1 and -2.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.

Author: BoffitoMarta, MaitlandDesmond, PozniakAnton

Drug interactions

This study reviews the pharmacokinetic interactions between tipranavir/ritonavir and other antiretroviral medications and drugs used to treat opportunistic infections in HIV-positive patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.

Author: MukwayaGeoffrey, MacGregorThomas, HoelscherDavid, HemingThomas, LeggDaniel, KavanaughKelli, JohnsonPhillip, SaboJohn P, McCallisterScott

Diarrhea treatment
Respiratory depression

This study examined the safety of loperamide when used with protease inhibitors, which are known to increase loperamide levels in the brain. Tipranavir reduced loperamide levels, while ritonavir increased them. Despite these pharmacokinetic changes, loperamide did not cause respiratory depression or pupil constriction in any of the study participants.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

11.

Targeting the HIV-protease in AIDS therapy: a current clinical perspective.

Author: TomasselliA G, HeinriksonR L

AIDS treatment
HIV protease inhibitor
Side effects
Viral resistance

This review discusses the clinical applications of HIV protease inhibitors. These drugs are effective in the treatment of AIDS but can cause viral resistance and side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.

Author: EmmelkampJ M, RockstrohJ K

Antiretroviral therapy
HIV infection control
Hepatotoxicity
Malignancy

CCR5 antagonists, like Maraviroc and Vicriviroc, block the interaction of HIV with the CCR5 chemokine receptor, inhibiting fusion with host cells. They have shown promising antiviral activity and are entering clinical practice.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.